Neurol. praxi. 2019;20(3):219-224 | DOI: 10.36290/neu.2019.116

Quality of life in patients with Parkinson´s disease in the Slovak Republic

RNDr. Vladimír Meluš, PhD., PhDr. Nikoleta Poliaková, PhD., doc. MUDr. Ján Bielik, CSc., PhDr. Simona Lipovská
Fakulta zdravotníctva, Trenčianska univerzita Alexandra Dubčeka v Trenčíne

Goal: The goal of the study was to determine the quality of life (QoL) of patients with Parkinson's disease and their work ability
(WA) in relation to certain demographic, clinical and social-economical parameters.
Sample and methods: The research used an original patient questionnaire predominantly based on an evaluation using a numerical
scale. QoL and WA were assessed by patients retrospectively in time of diagnosis, in time without disease, and in time
of so-called full-health. The results were processed and evaluated using descriptive statistics, Friedman's and Dunn's test. The
correlation rates between variables were confirmed by non-parametric Spearman correlative. Patients had an average age – 66.14
years, and 10 patients had fulltime jobs.

Results: Mean duration of illness was 8.33 years and mean time of the onset of symptoms before diagnosis was 2.17 years. Current
QoL and WA were 5.1 and 3.6 (0 – worst, 10 – best), in time of diagnosis – 5.8 and 5.1, before diagnosis – 8.2 and 8.6, and in time of
full health 8.8 and 9.1. The effect of treatment on QoL of patients was 5.82 and the impact of disease on QoL of family members beloved was 5.84 on the same scale. Aggravation of the relationship due to illness was assessed as follows: in the family – 2.23,
in the employment – 2.26, in the social life – 2.73 and in the interest activity – 3.22 (1 – without, 5 – maximum). Average time
of non-ability to work was 6.7 during the past 12 months. Mean monthly income (wage or benefits) was 386.6 €, patients paid
monthly 48 € for medical treatment. Patients were willing to pay 166 € monthly for hypothetical full health recovery.

Conclusion: The illness has significant impact on Qol and WA, both correlated strongly with each other. WA is regarded more
sensitively than Qol. Treatment lowers the rate of QoL degression: its effect on QoL is seen as positive. The disease impacts the
quality of life of family members, work and social relationships as well as inability to work.

Keywords: Parkinson's disease, quality of life, ability to work

Published: June 12, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Meluš V, Poliaková N, Bielik J, Lipovská S. Quality of life in patients with Parkinson´s disease in the Slovak Republic. Neurol. praxi. 2019;20(3):219-224. doi: 10.36290/neu.2019.116.
Download citation

References

  1. Baláž M, Bočková M, Bareš M, Rektorová I, Dírerová V, Rektor I. Kvalita života po hluboké mozkové stimulaci u pacientů s pokročilou Parkinsonovou nemocí. Cesk Slov Neurol N. 2011; 74/107(5): 564-568.
  2. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003 Mar; 18(3): 267-74. Go to original source... Go to PubMed...
  3. Bielik J, Ondrušová A, Matišáková I, Gerlichová K, Poliaková N, Mišinová M. Nový koncept kvality života s prenosom do rokov života štandardizovanej kvality aplikovanej do liekovej politiky. Farmakoekonomika a lieková politika 2013; 9(4): 14-18.
  4. Bowling A. Health-related quality of life: a discussion of the concept, its use and measurement. In: Measuring disease. Buckingham: Open University Press; 1995: 1-19.
  5. Campenhausen S, Winter Y, Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Bötzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP. Costs of illness and care in Parkinson's Disease: An evaluation in six countries. Eur Neuropsychofarmacol. 2011 Feb; 21(2): 180-91. Go to original source... Go to PubMed...
  6. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord. 2007; 22(11): 1528-37. Go to original source... Go to PubMed...
  7. Deshpande PR, Rajan S, Sudeepthi BL, Nazir CPA. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011; 2(4): 137-144. Go to original source...
  8. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006; 23(9): 693-721. Go to original source...
  9. EuroQoL Group EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208. Go to original source...
  10. European Parkinson's Disease Association (EPDA). Prevalence of Parkinson's Disease, 2014. [cit. 2014-03-05]. Available at: <http://www.epda.eu.com/en/parkinsons/life-with-parkinsons/part-1/prevalence-of-parkinsons-disease/>.
  11. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74(2): 163-169. Go to original source...
  12. Gmitterová K, Minár M, 1, Košutzká Z, Valkovič P. Terapia pokročilých štádií Parkinsonovej choroby invazívnymi postupmi. Cesk Slov Neurol N. 2017; 80/113(5): 503-516. Go to original source...
  13. Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord. 2005; 20(5): 616-9. Go to original source... Go to PubMed...
  14. Hagell P, Törnqvist AL, Hobart J. Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data. J Neurol. 2008 Feb; 255(2): 246-54. Go to original source... Go to PubMed...
  15. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013; 14(12): 1165-74. Go to original source... Go to PubMed...
  16. Marinus J, Ramaker C, van Hilten AM, Stiggelbout A. Health related quality of life in Parkinson's disease: a systematic review of disease specific Instruments. J Neurol Neurosurg Psychiatry 2002; 72(2): 241-248. doi: 10.1136/jnnp.72.2.241. Go to original source... Go to PubMed...
  17. Matišáková I, Bielik J, Kormancová R, Bystrický B, Meluš V. Quality of Life in Patients with Breast Cancer in Slovakia. Value in Health 2015; 18(7): A475. Go to original source...
  18. Matišáková I, Bielik J, Tužinčinová K, Meluš V, Bystrický B, Kliment J, Sokol R. The quality of life in patients with kidney cancer. University review 2015; 9(2-3): 12-16.
  19. Matišáková I, Kamenská E, Mastiliaková D, Meluš V, Bielik J, Novák I, Andrášová E. Quality of life in patients with chronic lumboiciatic syndrome in the Slovak Republic. Value in Health 2014; 17(7): A387. Go to original source... Go to PubMed...
  20. Morley D, Dummett S, Peters M, Kelly L, Hewitson P, Dawson J, Fitzpatrick R, Jenkinson C. Factors Influencing Quality of Life in Caregivers of People with Parkinson's Disease and Implications for Clinical Guidelines. Parkinson's Disease 2012; Volume 2012 (2012), Article ID 190901:6 pages. Go to original source...
  21. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012; 19(1): 155-62. Go to original source...
  22. Opara J. Current possibilities of evaluation of quality of life in Parkinson disease. Neurol Neurochir Pol. 2003; 37(Suppl 5): 241-50. Go to PubMed...
  23. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measure. J Neurol 1998; 245(Suppl 1): S10-S14. doi: 10.1007/PL00007730. Go to original source...
  24. Poliaková N, Lipovská S, Meluš V, Bielik J. Potenciál vlivu léčby intestinálním gelem levodopa a karbidopa na kvalitu života a schopnost pracovat u pacientů s Parkinsonovou nemocí. Neurol. praxi 2016; 17(5): 323-32. Go to original source...
  25. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D - a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000 Jul; 69(1): 67-73. Go to original source... Go to PubMed...
  26. Skorvanek M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, Valkovic P, Gdovinova Z, van Dijk JP. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease. Journal of the Neurological Sciences 2015; 353: 87-91. Go to original source... Go to PubMed...
  27. Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Valkovic P, Goetz CG, Stebbins GT. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism and Related Disorders 2018; 52: 83-89. Go to original source...
  28. Soh SE, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson's disease: a systematic review. Parkinsonism Relat Disord. 2011; 17(1): 1-9. Go to original source...
  29. Stewart KC, Fernandez HH, Okun MS, Jacobson CE, Hass CJ. Distribution of motor impairment influences quality of life in Parkinson's disease. Mov Disord. 2008; 23: 1466-1468. Go to original source... Go to PubMed...
  30. Stocchi F, Martinez-Martin P, Reichmann H. Quality of Life in Parkinson's Disease - Patient, Clinical and Research Perspectives. European Neurological Review 2014; 9(1): 12-8. Go to original source...
  31. Valkovič P. Súčasný pohľad na Parkinsonovu chorobu. Via pract. 2006; 3(5): 256-261.
  32. Valkovič P, Košutzká Z, Schmidt F. Posturálna instabilita, poruchy chôdze a pády pri Parkinsonovej chorobe. Cesk Slov Neurol N. 2012; 75/108(2): 141-151.
  33. Valkovic P, Minar M, Singliarova H, Harsany J, Hanakova M, Martinkova J, Benetin J. Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. PLoS ONE 2015; 10(8): e0136541. Go to original source... Go to PubMed...
  34. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) 1: conceptual framework and item selection. Med Care. 1992; 30(6): 473-483. Go to original source...
  35. Winter Y, Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, Ruzicka E. Costs of Parkinson's disease in Eastern Europe: A Czech cohort study. Parkinsonism and Related Disorders 2010; 16(1): 51-56. doi: https://doi.org/10.1016/j.parkreldis.2009.07.005. Go to original source...
  36. Ymanishi T. Anxiety and Depression in Patients with Parkinson's Disease. Intern Med. 2013; 52: 539-545. doi: 10.2169/internalmedicine.52.8617. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.